Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Subscribe To Our Newsletter & Stay Updated
